Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the overall response rate after 4 cycles and the best response to
induction therapy with combination of lenalidomide, subcutaneous bortezomib, and
dexamethasone (RsqVD) in patients with newly diagnosed multiple myeloma.